

SARC Semi-annual Meeting Agenda

8:00	Introduction	
	Welcome	
8:15	Chawla Rosenfeld Developmental Therapeutics	
	Introduction	C. Khanna
	A Case for Open-Source Drug Discovery	J. Bradner
	Anti-angiogenic activity of JQ1 in Sarcomas	H. Bid
	The Sarcoma Data Portal: Making High Content Sarcoma Datasets Available For All Users	J. Keats
	<i>Discussion/Q&A</i>	C. Khanna
9:35	SARC Career Development	
	Career Development 2014 Program	R. Gorlick & L. Helman
	Genome-wide functional characterization of GIST: Strategies to maximize kinase-inhibitor response	A. Marino-Enriquez
	Exploiting Argininosuccinate 1 deficiency in Sarcoma	B. Van Tine
	<i>Discussion/Q&A</i>	R. Gorlick & L. Helman
10:20	Break	
10:30	SARC Clinical Trials	
	Clinical Trials Update	S. Okuno
	SARC012: Phase 2 trial of saracatinib in resected recurrent osteosarcoma	M. Merchant
	SARC016: Phase 2 trial of bevacizumab & everolimus in unresectable or metastatic MPNST	L. Helman
	SARC020/EORTC: Phase 2b/3 study of trabectedin versus doxorubicin for first-line therapy of metastatic STS	J. Butrynski
	SARC021: Phase 3 trial of TH-302+doxorubicin versus doxorubicin in advanced/metastatic STS	W. Tap
	SARC022: Phase 2 trial of linsitinib in pediatric and adult wild-type GIST	M. von Mehren
	SARC023: Phase 2 trial of ganetespib & sirolimus in unresectable or metastatic MPNST	L. Helman
	SARC024: Phase 2 trial of regorafenib in refractory lipo, osteo and Ewing/Ewing-like sarcomas	R. Maki
	SARC025: Phase 1 trial of niraparib and temozolomide in incurable Ewing sarcoma	S. Strauss
11:15	SARC Sarcoma SPORE	
	Update SARC Sarcoma SPORE	R. Pollock
11:25	Business	
	SARC Participant Policy	D. Reinke